Document is current
Any future updates will be listed below
-
Authors
Hayama, Koremasa https://orcid.org/0000-0001-8651-2493
Chinuki, Yuko
Yagami, Akiko
Kume, Akihiro
Morita, Atsuya
Miyazu, Sakiko
Lheritier, Karine
Jaskiewicz, Lukasz
Haemmerle, Sibylle
Hide, Michihiro
-
Funding
Funding for this research was provided by:
Novartis Pharma
- License Information
-
More Information
Article History
Received: 4 November 2025
Accepted: 22 January 2026
First Online: 19 February 2026
Declarations
:
: Koremasa Hayama was the principal investigator for the BISCUIT trial and an advisor for Novartis, Sanofi, and Boehringer Ingelheim. He received honoraria for lectures from Kaken Pharmaceutical, Kyowa Kirin, Kyorin Pharmaceutical, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Novartis, Sanofi, Taiho Pharmaceutical, and Boehringer Ingelheim and grants for his facility from Kaken Pharmaceutical, Kyorin Pharmaceutical, Kyowa Kirin, Mitsubishi Tanabe Pharma, and Taiho Pharmaceutical. Yuko Chinuki received honoraria for lectures from Novartis, Mitsubishi Tanabe Pharma, Sanofi, Taiho Pharmaceutical, Kaken Pharmaceutical, and Meiji Seika Pharma. Akiko Yagami received honoraria for lectures from Novartis, AbbVie, Otsuka Pharmaceutical, Kaken Pharmaceutical, Sanofi, Taiho Pharmaceutical, Tanabe Pharma, Torii Pharmaceutical, Eli Lilly Japan KK, Pfizer, Maruho and LEO Pharma and received grants from Novartis, Sanofi, and Maruho. Akihiro Kume has no conflict of interest to disclose. Atsuya Morita and Sakiko Miyazu are employees of Novartis Pharma K.K., Tokyo, Japan. Karine Lheritier, Lukasz Jaskiewicz, and Sibylle Haemmerle are employees of Novartis Pharma AG, Basel, Switzerland. Michihiro Hide has received lecture and/or consultation fees from Japan Tabacco, Kaken Pharmaceutical, Kyorin Pharmaceutical, Kyowa Kirin, Meiji Seiyaku, Mitsubishi Tanabe Pharma, Nippon Zoki, Novartis, Sanofi, Taiho Pharmaceutical, Teikoku Seiyaku and Yuhan. Michihiro Hide is an Editorial Board member of Dermatology and Therapy and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.
: The sponsor (Novartis Pharma AG, Basel, Switzerland) and the program steering committee collaboratively designed the study and interpreted the data. The study was conducted in accordance with the principles of the Declaration of Helsinki, Good Clinical Practice guidelines, and applicable local regulations. Investigators/institutions obtained approval from the institutional review board/independent ethics committees for the study protocol before starting the study. All participants provided written informed consent.
